Tempest Minerals Ltd is engaged in the exploration of precious metals, base metals, and energy metals. The projects include Range Project, Messenger Project, Rocky Hill Project, Warriedar and many more. The firm has one reportable segment, being the exploration of mineral projects in Western Australia. Geographically it operates in Australia, Zimbabwe and Mozambique and derives key revenue from Australia.
相关临床试验
14
2 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
2
14.3%
已完成
2
14.3%
招募中
9
64.3%
终止
1
7.1%
暂无批准数据
- Whitehawk Therapeutics presented two real-world analyses at WCLC 2026 showing PTK7 expression remains largely stable in EGFR wild-type lung adenocarcinoma after standard-of-care therapy. - PTK7 showed less treatment-associated variation than late-stage ADC targets MET, PD-L1 and ITGB6, and was consistent across tumors with or without other actionable genomic alterations. - A separate analysis found PTK7 expression was not independently associated with real-world overall or progression-free survival, supporting it as a target-engagement biomarker rather than a prognostic marker. - The findings reinforce the rationale for HWK-007, a PTK7-directed next-generation ADC in an ongoing Phase 1 trial in EGFR wild-type NSCLC, platinum-resistant ovarian and endometrial cancer.
- Nucleai and Gilead Sciences are collaborating to apply AI-powered Tissue Intelligence to Gilead's global antibody-drug conjugate (ADC) clinical development programs across multiple oncology indications. - The collaboration has analyzed large datasets of H&E and IHC whole-slide images from several Gilead clinical studies, generating candidate spatial biomarkers for future scientific presentations and publications. - Nucleai's platform integrates computational pathology, spatial biology, and clinical outcomes data to map protein expression patterns, tumor heterogeneity, and the tumor microenvironment. - The partnership reflects growing industry recognition that AI-powered tissue analytics can strengthen biomarker development and precision medicine across oncology portfolios.
- Tempus AI announced a definitive agreement to acquire cancer test maker Personalis in a deal valued at approximately $1.5 billion, paid primarily in Tempus stock. - The acquisition centers on Personalis' NeXT Personal test, which uses minimal residual disease (MRD) technology to detect trace amounts of cancer after treatment via personalized genetic signatures. - Personalis shareholders will receive $16.25 per share, representing a 5.6% premium to the last closing price, with Tempus retaining the option to pay up to 50% in cash. - The deal builds on an existing partnership from November 2023 and is expected to close in late 2026 or early 2027, according to Tempus CEO Eric Lefkofsky.
- Nano Dimension and Infinite Epigenetics announced a proposed stock-for-stock merger valuing Infinite at $890 million, with Nano shares valued at a 20% premium to estimated net cash at closing. - The combined company will leverage Infinite's proprietary biological AI platform, a CLIA-certified methylation laboratory, and a database of over 120,000 biological samples across a network of more than 7,500 healthcare providers. - Infinite's platform targets earlier and more precise chronic disease detection through DNA methylation-based diagnostics, combining clinical testing, consumer longevity, pharma data, and enterprise health applications. - A definitive agreement is expected before July 31, 2026, with the combined company projected to hold over $400 million in cash at closing.
- Whitehawk Therapeutics presented real-world analysis at ASCO 2026 demonstrating that SEZ6 expression in small cell lung cancer exceeds approved and emerging ADC targets by at least 3-fold compared to HER2, B7-H3, DLL3, PD-L1 and PD-1. - The analysis revealed SEZ6 expression is highest in SCLC-A and SCLC-N molecular subtypes, which account for approximately 90% of all SCLC cases and are characterized by high neuroendocrine transcription factor expression. - SEZ6 expression positively correlates with DLL3 across neuroendocrine carcinomas, indicating potential for combination therapy approaches with existing DLL3-targeted treatments. - The company plans to submit an Investigational New Drug application for its biparatopic SEZ6-directed ADC HWK-206 in mid-2026, with Phase 1 trials expected to begin in Q3 2026.
- Verge Genomics has rebranded as Verge Labs and laid off 90% of its workforce after its AI-designed ALS drug VRG50635 failed in early-stage clinical trials. - The experimental drug, targeting the PIKfyve enzyme, showed increased levels of neurofilament light chain protein, indicating it wasn't having the desired therapeutic effect. - The company is pivoting from drug development to providing AI-driven data services for target identification, patient selection, and biomarker prediction. - CEO Alice Zhang emphasized that setbacks are expected with transformational technologies and that learnings will be fed back into the platform for iterative improvements.
- Pathos AI acquired a majority stake in DeuterOncology through its AI-powered Foundry platform, marking one of the first clinical-stage oncology acquisitions sourced and executed entirely through artificial intelligence. - The acquired asset DO-2 is a third-generation MET kinase inhibitor that demonstrated 100% tumor shrinkage in all evaluable MET exon 14 skipping NSCLC patients with only 5% peripheral edema rate versus 62-82% for competitors. - The Foundry platform systematically identified DO-2 from large-scale clinical datasets in late 2025, completing the entire evaluation and acquisition process in a fraction of traditional due diligence time.
- Tempus AI has announced a collaboration with Median Technologies to integrate the FDA-cleared eyonis® LCS AI-powered lung cancer screening device into its Tempus Pixel platform. - The eyonis® LCS system demonstrates 93.3% sensitivity, 92.4% specificity, and 99.9% negative predictive value for detecting and characterizing lung cancer in low-dose CT scans. - Only 20% of eligible Americans were screened for lung cancer in 2024, and achieving full participation could prevent an estimated 62,110 lung cancer deaths over five years. - The collaboration targets 14.5 million Americans eligible for lung cancer screening and builds on existing reimbursement pathways of $601-$700.
- Tempus AI's Immune Profile Score (IPS) test demonstrated superior accuracy in predicting immune checkpoint inhibitor outcomes compared to conventional biomarkers including tumor mutational burden, microsatellite instability, and PD-L1 across four independent validation cohorts. - The multimodal biomarker identified 13% of microsatellite stable colorectal cancer patients who showed strong real-world overall survival with immunotherapy treatment, potentially expanding treatment options for previously overlooked populations. - IPS classified 17% of rare metastatic solid tumor patients as "IPS-High" despite not meeting cancer-specific FDA-approved immunotherapy labels, showing significant survival differences that could guide treatment decisions. - The test is available as an add-on to Tempus' existing xT and xR sequencing assays, leveraging AI-driven analysis of DNA and RNA data to provide comprehensive immunotherapy response predictions.
- Tempus AI has launched Paige Predict, an AI-powered digital pathology solution that predicts biomarkers from H&E slide images when tissue samples are insufficient for molecular profiling. - The platform analyzes 123 biomarkers and oncogenic pathways across 16 cancer types, helping clinicians prioritize testing when tissue availability is limited. - Built using data from over 200,000 patients, Paige Predict addresses the critical challenge of "quantity not sufficient" samples that can delay patient care by days or weeks.
